Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France - Full Text View

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00681837

Purpose

The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management

Condition
Gastroesophageal Reflux

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Resource links provided by NLM:

MedlinePlus related topics: GERD

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

assess prevalence of gastrooesophageal reflux during childhood and teenage years in France, particularly 0-1 year-old prevalence and 1-11 year-old prevalence [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

describe patients'symptoms and gastrooesophageal reflux management [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2500
Study Start Date:	May 2008
Study Completion Date:	September 2008

Groups/Cohorts
1 children from 0 to 17 years old

Eligibility

Ages Eligible for Study:	up to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

children recruited by both GPs and paediatricians

Criteria

Inclusion Criteria:

children from 0 to 17years old seen in consultation

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00681837

Hide Study Locations

Locations

China
Research Site
Chongqing, China
Research Site
Shanghai, China
China, Anhui
Research Site
Hefei, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
Research Site
Xiamen, Guangdong, China
Research Site
Zhongshan, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hunan
Research Site
Changsha, Hunan, China
China, Jiangsu
Research Site
Nanjing, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
Research Site
Wuxi, Jiangsu, China
China, Jiangxi
Research Site
Nanchang, Jiangxi, China
China, Shandong
Research Site
Jinan, Shandong, China
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Taiyuan, Shanxi, China
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Yunnan
Research Site
Kunming, Yunnan, China
China, Zhejiang
Research Site
Hangzhou, Zhejiang, China
Research Site
Ningbo, Zhejiang, China
Research Site
Rui'an, Zhejiang, China
Research Site
Wenzhou, Zhejiang, China

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:	Frédéric GOTTRAND	CHRU Lille - France
Principal Investigator:	Geneviève BONNELYE	TNS Healthcare 92120 Montrouge - France

More Information

No publications provided

Responsible Party:	AstraZeneca ( Paula Fernstrom )
Study ID Numbers:	NIS-GFR-DUM-2008/1
Study First Received:	May 19, 2008
Last Updated:	November 17, 2008
ClinicalTrials.gov Identifier:	NCT00681837 History of Changes
Health Authority:	France: Haute Autorité de Santé Transparency Commission

Keywords provided by AstraZeneca:

gastroesophageal reflux
prevalence
childhood
France

Additional relevant MeSH terms:

Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases

Gastrointestinal Diseases
Esophageal Diseases
Gastroesophageal Reflux

ClinicalTrials.gov processed this record on November 30, 2009